[Skip to Navigation]
Sign In
Editor's Correspondence
August 10/24, 1998

Cost-effective Treatment of Hypercholesterolemia

Arch Intern Med. 1998;158(15):1723-1724. doi:

In reply

We agree with Parsons that a niacin/lovastatin combination could be highly cost-effective, provided that patient compliance is high. Clearly, a cost-benefit analysis should be driven by long-term estimates of compliance. Unfortunately, observational data suggest that compliance rates with niacin are lower than that with other lipid-lowering drugs.1

Add or change institution